Source: Yaoshi Zongheng

A new report from Evaluate forecasts that total global prescription-drug sales will reach US$ 1.75 trillion by 2030, with GLP-1 therapies expected to post a 20 % compound growth from 2024–2030 and to account for 9 % of all drug sales that year. Below is Evaluate’s projected ranking of the top-selling drugs in 2030.

1. Mounjaro

   Company: Eli Lilly  

   2024 sales: US$ 11.5 billion  

   2030 forecast: US$ 36.2 billion  

   On 13 May 2022 the FDA approved Eli Lilly’s once-weekly dual GIP and GLP-1 receptor agonist Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

2. Skyrizi

   Company: AbbVie  

   2024 sales: US$ 11.7 billion  

   2030 forecast: US$ 26.6 billion  

   As of June 2024 Skyrizi holds seven indications, including plaque psoriasis, psoriatic arthritis and Crohn’s disease. AbbVie is advancing additional Phase III studies in juvenile psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.

3. Zepbound

   Company: Eli Lilly  

   2024 sales: US$ 4.9 billion  

   2030 forecast: US$ 25.5 billion  

   Mounjaro (diabetes) and Zepbound (weight management) together contributed US$ 16.5 billion in 2024. In December 2024 the FDA cleared Zepbound as the first and only Rx treatment for moderate-to-severe obstructive sleep apnoea in adults with obesity. Evaluate projects the two tirzepatide brands to generate US$ 62 billion in 2030—triple Humira’s peak and double Keytruda’s 2024 sales.

4. Dupixent

   Company: Sanofi / Regeneron  

   2024 sales: US$ 14.1 billion  

   2030 forecast: US$ 25.1 billion  

   Dupixent is a fully human monoclonal antibody that blocks IL-4 and IL-13 signalling. Approved in more than 60 countries for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria and COPD. On 21 June 2025 it became the first FDA-approved therapy for bullous pemphigoid.

5.Ozempic

   Company: Novo Nordisk  

   2024 sales: US$ 17.5 billion  

   2030 forecast: US$ 24.4 billion  

6. Wegovy

   Company: Novo Nordisk  

   2024 sales: US$ 8.4 billion  

   2030 forecast: US$ 18.1 billion  

   Combined sales of Ozempic, Wegovy and oral Rybelsus reached ~US$ 29.3 billion in 2024, accounting for more than two-thirds of Novo Nordisk’s revenue.

7. Keytruda

   Company: Merck & Co.  

   2024 sales: US$ 29.5 billion  

   2030 forecast: US$ 16.9 billion  

   The leading PD-1 inhibitor faces biosimilar competition after key patents expire in 2028, making it the only top-ten drug with negative growth.

8. Darzalex

   Company: Johnson & Johnson / Genmab  

   2024 sales: US$ 11.7 billion  

   2030 forecast: US$ 16.6 billion  

   The anti-CD38 monoclonal antibody surpassed US$ 10 billion in 2024. Patents expire in 2026; J&J is pursuing new indications to offset generics.

9. Biktarvy

   Company: Gilead  

   2024 sales: US$ 13.5 billion  

   2030 forecast: US$ 15.7 billion  

   Biktarvy’s key patents protect it from generics until 2033, ensuring stable growth.

10. CagriSema

    Company: Novo Nordisk  

    2024 sales: US$ 0  

    2030 forecast: US$ 15.2 billion  

    A once-weekly co-formulation of semaglutide + cagrilintide for weight management and type 2 diabetes. NDA filing is planned for early 2026, launch anticipated 2027; Evaluate calls it the most promising pipeline asset, with peak sales potential of US$ 80 billion.

11. Enhertu

    Company: AstraZeneca / Daiichi Sankyo  

    2024 sales: US$ 4.2 billion  

    2030 forecast: US$ 15.2 billion  

    Since its 2019 launch Enhertu has been incorporated into 19 NCCN guidelines and approved in 60+ countries for breast and gastric cancer. Cumulative sales reached US$ 7.37 billion by early 2025; it is the global ADC revenue leader.

2030 Top-10 Pharma Companies (Forecast)

Reference:  

https://www.biospace.com/business/prescription-drug-sales-will-hit-1-75t-by-2030-thanks-to-glp-1s-evaluate